Wall Street Zen Upgrades Bambusa Therapeutics (NASDAQ:BBTX) to Hold

Bambusa Therapeutics (NASDAQ:BBTX – Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

Bambusa Therapeutics Price Performance

Bambusa Therapeutics stock opened at $16.00 on Friday. Bambusa Therapeutics has a 1-year low of $13.60 and a 1-year high of $17.65.

Insider Transactions at Bambusa Therapeutics

In related news, major shareholder Salvia Investment Gmbh acquired 375,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were bought at an average cost of $16.00 per share, for a total transaction of $6,000,000.00. Following the purchase, the insider owned 9,264,301 shares in the company, valued at $148,228,816. This trade represents a 4.22% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ra Capital Management, L.P. acquired 2,500,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were bought at an average cost of $16.00 per share, for a total transaction of $40,000,000.00. Following the acquisition, the director directly owned 5,933,787 shares in the company, valued at $94,940,592. This represents a 72.81% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 3,703,820 shares of company stock valued at $58,639,387 over the last three months.

About Bambusa Therapeutics

(Get Free Report)

Bambusa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation and fundamentally improve patient quality of life. Its pipeline includes BBT001, BBT002, BBT003 and BBT004. Bambusa Therapeutics, Inc. is based in BOSTON.

Featured Stories

Receive News & Ratings for Bambusa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bambusa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.